January 2012
 

• Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with
  rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
  Fleishaker DL, Garcia Meijide JA,  et al Arthritis Res Ther. 2012 Jan 17;14(1):R11.
• Novel agents for the treatment of HIV-2 infection.
  Peterson K, Rowland-Jones S. Antivir Ther. 2012 Jan 25.
• Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with
  Suppressed Plasma HIV-1-RNA Load.
  Vitiello P, Brudney D, Maccartney M,  et alIntervirology. 2012;55(2):172-8
• A WEEK-IN-REVIEW FEATURED REPORT
  Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in
  HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
  Macías J, Viloria MM, Rivero A, et al Eur J Clin Microbiol Infect Dis. 2012 Jan 19.
• Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus
  Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-).
  Antoniou T, Smith G, Su D, et al J Int Assoc Physicians AIDS Care (Chic